TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 24164375

Group type: EXPERIMENTAL
Intervention: FIT group: mailed the FIT, plus educational materials and survey (N = 500)
Number of subjects: 1499

Group type: COMPARATOR
Intervention: Education only (Ed) group: mailed CRC educational materials and a survey of screening history and preferences (N = 499)
Number of subjects: 1499

Group type: COMPARATOR
Intervention: Usual care (UC) group: received no mailings (N = 500)
Number of subjects: 1499
Study: 22682988

Group type: EXPERIMENTAL
Intervention: Cognitive remediation training (N=17)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Active control (TV-watching; N=17)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Treatment-as-usual (N=10)
Number of subjects: 44
Study: 21107105

Group type: EXPERIMENTAL
Intervention: Paramedic rapid sequence intubation
Number of subjects: 312

Group type: COMPARATOR
Intervention: Hospital intubation
Number of subjects: 312
Study: 19082219

Group type: EXPERIMENTAL
Intervention: High-flow nitrous oxide anesthesia (HFA)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Low-flow nitrous oxide anesthesia (LFA)
Number of subjects: 70
Study: 17053895

Group type: EXPERIMENTAL
Intervention: Artemether and lumefantrine (AL) treatment
Number of subjects: 13

Group type: COMPARATOR
Intervention: Non-pregnant adults (control group)
Number of subjects: 13
Study: 12837873

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate aqueous nasal spray (FP) 200 microg/day for 6 weeks
Number of subjects: 65

Group type: COMPARATOR
Intervention: Placebo (vehicle) for 6 weeks
Number of subjects: 65
Study: 10717490

Group type: EXPERIMENTAL
Intervention: Estrogen replacement therapy (ERT, conjugated equine estrogen 0.625 mg orally daily)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Combined estrogen and continuous progestogen therapy (HRT, 0.625 mg of conjugated equine estrogens plus medroxyprogesterone acetate 5 mg daily)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 8856585

Group type: EXPERIMENTAL
Intervention: Intravenous atropine sulfate (0.04 mg/kg/day, increased by 0.01 mg/kg/day until vomiting ceased)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Oral atropine sulfate (twice the effective intravenous dose) continued for 2 weeks after intravenous treatment
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Ultrasonography after intravenous atropine treatment
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Intravenous atropine sulfate
Number of subjects: 23
Study: 1738379

Group type: EXPERIMENTAL
Intervention: Meglumine antimoniate plus allopurinol
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Allopurinol alone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Meglumine antimoniate alone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Untreated patients
Number of subjects: 0
Study: 6469181

Group type: EXPERIMENTAL
Intervention: Glucosamine sulphate
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Glycosaminoglycan polysulphate
Number of subjects: 68
Study: 30864528

Group type: EXPERIMENTAL
Intervention: Oxcarbazepine (OXC) monotherapy
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: New antiepileptic drugs (NADs)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Healthy participants
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Total health status
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Main groups of NADs
Number of subjects: 80
Study: 30848415

Group type: EXPERIMENTAL
Intervention: Coping Power intervention
Number of subjects: 118
Study: 30044293

Group type: EXPERIMENTAL
Intervention: Continuation of oral hypoglycemics (OHDs)
Number of subjects: 142

Group type: COMPARATOR
Intervention: Withholding oral hypoglycemics (OHDs)
Number of subjects: 142
Study: 24690440

Group type: EXPERIMENTAL
Intervention: Core vitrectomy additional to three times injections of ranibizumab (3x Rbz)
Number of subjects: 50

Group type: COMPARATOR
Intervention: 3x Rbz (control)
Number of subjects: 50
Study: 22179538

Group type: EXPERIMENTAL
Intervention: Trandolapril
Number of subjects: 3717

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3717
Study: 20104770

Group type: COMPARATOR
Intervention: Hepatitis B vaccine 10 microg each time (group A)
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: rhGM-CSF 300 microg on the first day, then 10 microg each time for routine immune (group B)
Number of subjects: 67
Study: 17502347

Group type: EXPERIMENTAL
Intervention: Refrigerator-stable formulation of ProQuad
Number of subjects: 1519

Group type: COMPARATOR
Intervention: Frozen formulation of ProQuad
Number of subjects: 1519
Study: 14969836

Group type: EXPERIMENTAL
Intervention: IFN 3 MIU daily for 4 weeks, followed by tiw up to 12 months
Number of subjects: 59

Group type: COMPARATOR
Intervention: IFN 3 MIU daily for 12 weeks, followed by tiw up to 12 months
Number of subjects: 59
Study: 11675061

Group type: EXPERIMENTAL
Intervention: LY334370 20 mg
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: LY334370 60 mg
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: LY334370 200 mg
Number of subjects: 99

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 99
Study: 9036906

Group type: EXPERIMENTAL
Intervention: Contraction of the tibialis anterior muscle at 25, 50, 75, and 100% of maximum force
Number of subjects: 10
Study: 7699639

Group type: EXPERIMENTAL
Intervention: Yoga program supervised by one instructor once/week for 8 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: No therapy (control group)
Number of subjects: 0
Study: 3035849

Group type: EXPERIMENTAL
Intervention: Naloxone (100 micrograms/kg bolus followed by 50 micrograms X kg‐1 X h‐1 infusion)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Control (corresponding volume of preservatives as bolus followed by infusion of diluted preservatives)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Naloxone
Number of subjects: 9

Group type: COMPARATOR
Intervention: Control
Number of subjects: 9
Study: 30194197

Group type: EXPERIMENTAL
Intervention: Laparoscopic cholecystectomy (LC)
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Mini-cholecystectomy (MC)
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: High plasma levels of catalase
Number of subjects: 114
Study: 27275798

Group type: EXPERIMENTAL
Intervention: Pelvic floor exercises training and insertion of a vaginal pessary (pessary group)
Number of subjects: 276

Group type: COMPARATOR
Intervention: Pelvic floor exercises training (control group)
Number of subjects: 276
Study: 24091306

Group type: COMPARATOR
Intervention: Short-term psychotherapy (solution-focused or short-term psychodynamic)
Number of subjects: 326

Group type: EXPERIMENTAL
Intervention: Long-term psychodynamic psychotherapy
Number of subjects: 326
Study: 22118629

Group type: EXPERIMENTAL
Intervention: Oseltamivir
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study: 20869680

Group type: EXPERIMENTAL
Intervention: Sonographically guided ACJ injections
Number of subjects: 20

Group type: COMPARATOR
Intervention: Palpation-guided ACJ injections
Number of subjects: 20
Study: 18976393

Group type: EXPERIMENTAL
Intervention: Quadrant-wise mechanical debridement (QMD)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Single-visit full-mouth mechanical debridement (FMD) with povidone iodine
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Single-visit full-mouth mechanical debridement (FMD) with water
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control group (QMD)
Number of subjects: 36
Study: 16184837

Group type: COMPARATOR
Intervention: BAV patients without significant aortic stenosis or regurgitation (n = 10, mean age 27 +/- 8 years)
Number of subjects: 28

Group type: COMPARATOR
Intervention: BAV patients with moderate or severe aortic regurgitation (n = 18, mean age 32 +/- 9 years)
Number of subjects: 28
Study: 12805329

Group type: EXPERIMENTAL
Intervention: Supportive care with clinical evaluation for ascites and physical performance status, and measurement of serum alpha-fetoprotein (AFP).
Number of subjects: 397

Group type: EXPERIMENTAL
Intervention: Validation group of 324 HCC patients from an Asia-Pacific-wide randomized trial.
Number of subjects: 397
Study: 14628189

Group type: EXPERIMENTAL
Intervention: Zydis Selegiline 10 mg
Number of subjects: 156

Group type: COMPARATOR
Intervention: Conventional selegiline tablets 10 mg
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: Zydis Selegiline 1.25 mg
Number of subjects: 156
Study: 10590283

Group type: EXPERIMENTAL
Intervention: Azithromycin (1200 mg/week)
Number of subjects: 0

Group type: COMPARATOR
Intervention: No prophylaxis
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Azithromycin
Number of subjects: 0
Study: 8829718

Group type: EXPERIMENTAL
Intervention: Original trial medication
Number of subjects: 423

Group type: EXPERIMENTAL
Intervention: Continuous use of psychotropic medication during follow-up
Number of subjects: 423

Group type: EXPERIMENTAL
Intervention: Longer duration of illness
Number of subjects: 423

Group type: EXPERIMENTAL
Intervention: More severe phobic avoidance at baseline
Number of subjects: 423

Group type: EXPERIMENTAL
Intervention: Follow-up results
Number of subjects: 423
Study: 2090158

Group type: EXPERIMENTAL
Intervention: Interplak Home Plaque Removal Instrument
Number of subjects: 12

Group type: COMPARATOR
Intervention: Braun Electric Toothbrush
Number of subjects: 12
Study: 386061

Group type: EXPERIMENTAL
Intervention: Atenolol 50 mg twice a day
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Atenolol 100 mg twice a day
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Atenolol 100 mg once a day
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Oxprenolol 80 mg twice a day
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Oxprenolol 160 mg twice a day
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study: 28213385

Group type: EXPERIMENTAL
Intervention: Acarbose (100 mg)
Number of subjects: 91

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 91
Study: 26508370

Group type: EXPERIMENTAL
Intervention: Migraine patients
Number of subjects: 52

Group type: COMPARATOR
Intervention: Healthy subjects (control group)
Number of subjects: 52
Study: 23394742

Group type: EXPERIMENTAL
Intervention: Amisulpride
Number of subjects: 383

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 383
Study: 21081579

Group type: EXPERIMENTAL
Intervention: MRI
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Sonography
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Mammography
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Clinical Examination
Number of subjects: 43
Study: 19153121

Group type: EXPERIMENTAL
Intervention: Capecitabine/cisplatin (XP)
Number of subjects: 316

Group type: COMPARATOR
Intervention: 5-fluorouracil/cisplatin (FP)
Number of subjects: 316
Study: 18180581

Group type: EXPERIMENTAL
Intervention: Various treatment methods for cartilage defects, specific interventions not detailed, timing and methods of treatment unclear.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Arthroscopic evaluation for diagnosis, considered the gold standard.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Natural course of cartilage defects, treatment methods not specified.
Number of subjects: 0
Study: 14753327

Group type: EXPERIMENTAL
Intervention: Vitremer in De‐Re‐ solutions
Number of subjects: 24

Group type: COMPARATOR
Intervention: Other materials in H2O and AS
Number of subjects: 24
Study: 11340534

Group type: EXPERIMENTAL
Intervention: Prophylaxis with clarithromycin, trimethoprim and sulfamethoxazole, or both
Number of subjects: 394

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 394
Study: 9273875

Group type: EXPERIMENTAL
Intervention: 5 mg/m3 zinc oxide
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: 2.5 mg/m3 zinc oxide
Number of subjects: 13

Group type: COMPARATOR
Intervention: Air exposure (control)
Number of subjects: 13
Study: 7958542

Group type: EXPERIMENTAL
Intervention: Glibenclamide 1.75 mg
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Glibenclamide 3.5 mg
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Glibenclamide 7.0 mg
Number of subjects: 9

Group type: COMPARATOR
Intervention: AG 1.0 mg
Number of subjects: 9

Group type: COMPARATOR
Intervention: AG 2.0 mg
Number of subjects: 9

Group type: COMPARATOR
Intervention: AG 4.0 mg
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Glibenclamide (all doses)
Number of subjects: 9

Group type: COMPARATOR
Intervention: AG (all doses)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Both drugs
Number of subjects: 9
Study: 2885301

Group type: EXPERIMENTAL
Intervention: Propranolol (PROP, 80 mg twice daily)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Atenolol (ATEN, 100 mg once a day)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo (PLAC)
Number of subjects: 28
Study: 31685489

Group type: EXPERIMENTAL
Intervention: Metabolic bariatric surgery (MBS)
Number of subjects: 93

Group type: COMPARATOR
Intervention: Medical treatment (metformin alone or in combination with rosiglitazone or intensive lifestyle intervention)
Number of subjects: 93
Study: 31062044

Group type: EXPERIMENTAL
Intervention: Knotless cinch-bridge technique
Number of subjects: 37

Group type: COMPARATOR
Intervention: Suture-bridge technique
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Both techniques
Number of subjects: 37
Study: 28454794

Group type: EXPERIMENTAL
Intervention: Intravascular ultrasound-guided PCI with the novel everolimus-eluting platinum-chromium Synergy stent followed by 4 months of dual antiplatelet therapy (DAPT)
Number of subjects: 818

Group type: COMPARATOR
Intervention: Everolimus-eluting cobalt-chromium Xience stent followed by 12 months of DAPT
Number of subjects: 818
Study: 25352691

Group type: EXPERIMENTAL
Intervention: Chlamydia trachomatis (CT), Neisseria gonorrhoeae (NG), and Trichomonas vaginalis (TV) testing
Number of subjects: 13480

Group type: EXPERIMENTAL
Intervention: Chlamydia trachomatis (CT) and Neisseria gonorrhoeae (NG) co-infection
Number of subjects: 13480

Group type: EXPERIMENTAL
Intervention: All three infections (CT, NG, TV)
Number of subjects: 13480

Group type: EXPERIMENTAL
Intervention: Coinfection positivity
Number of subjects: 13480

Group type: EXPERIMENTAL
Intervention: Trichomonas vaginalis (TV) association with other infections
Number of subjects: 13480
Study: 23576210

Group type: EXPERIMENTAL
Intervention: Cutting balloon angioplasty (CBA)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Conventional balloon angioplasty (PTA)
Number of subjects: 60
Study: 22314719

Group type: EXPERIMENTAL
Intervention: Magnetotherapeutic device (MTD) applied externally to the site of pain (maximum magnetic flux density, 55 +/- 5 mT; length, 500 mm; diameter, 4.5 mm)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Non-MTD (sham control, 0 mT; 500 mm; diameter, 4.5 mm)
Number of subjects: 62
Study: 19154471

Group type: EXPERIMENTAL
Intervention: sorafenib
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: sunitinib
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: temsirolimus
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: bevacizumab (in combination with interferon)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: everolimus
Number of subjects: 0
Study: 17537090

Group type: EXPERIMENTAL
Intervention: Exercise training (including progressive endurance and resistance training)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Relaxation (attention control)
Number of subjects: 66
Study: 15130715

Group type: EXPERIMENTAL
Intervention: Visual biofeedback training
Number of subjects: 27

Group type: COMPARATOR
Intervention: Traditional balance training
Number of subjects: 27
Study: 11676993

Group type: EXPERIMENTAL
Intervention: ALS patients performing a bicycle incremental test
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: ALS patients during exercise
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: ALS patients
Number of subjects: 11
Study: 9648079

Group type: EXPERIMENTAL
Intervention: Free pentosidine
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: Neopterin
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: Baseline increases in free pentosidine and neopterin
Number of subjects: 134

Group type: COMPARATOR
Intervention: Protein-bound pentosidine
Number of subjects: 134

Group type: COMPARATOR
Intervention: IL-6 and CRP
Number of subjects: 134
Study: 8129059

Group type: EXPERIMENTAL
Intervention: 70% return air (index phase)
Number of subjects: 75

Group type: COMPARATOR
Intervention: 0% return air (reference phase)
Number of subjects: 75
Study: 2510284

Group type: EXPERIMENTAL
Intervention: Rioprostil (single oral dose)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Rioprostil (repeated evening doses)
Number of subjects: 0
Study: 796739

Group type: EXPERIMENTAL
Intervention: Alternate-day prednisone therapy
Number of subjects: 53

Group type: COMPARATOR
Intervention: Daily prednisone
Number of subjects: 53
Study: 31930358

Group type: EXPERIMENTAL
Intervention: Coaching Boys Into Men (CBIM) program
Number of subjects: 973
Study: 31381157

Group type: EXPERIMENTAL
Intervention: 0.454% stannous fluoride test toothpaste
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sodium monofluorophosphate‐based control
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pooled analysis of 0.454% stannous fluoride test toothpaste
Number of subjects: 0
Study: 28035910

Group type: EXPERIMENTAL
Intervention: Cervical unilateral anterior-posterior mobilisation
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo cervical unilateral A-P light touch pressure
Number of subjects: 32
Study: 26150444

Group type: EXPERIMENTAL
Intervention: Consolidation chemotherapy (CC) with docetaxel and cisplatin (DP) after concurrent chemoradiotherapy (CCRT) with the same agents.
Number of subjects: 420

Group type: COMPARATOR
Intervention: CCRT with docetaxel (20 mg/m(2)) and cisplatin (20 mg/m(2)) administered weekly for 6 weeks.
Number of subjects: 420

Group type: EXPERIMENTAL
Intervention: Consolidation chemotherapy (CC) with docetaxel and cisplatin (DP) after CCRT.
Number of subjects: 420

Group type: COMPARATOR
Intervention: CCRT with docetaxel and cisplatin (DP).
Number of subjects: 420
Study: 24662902

Group type: EXPERIMENTAL
Intervention: Arthroplasty group (knee replacement)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Control group (healthy persons)
Number of subjects: 62
Study: 21672123

Group type: EXPERIMENTAL
Intervention: Dapagliflozin 2.5 mg/day
Number of subjects: 597

Group type: EXPERIMENTAL
Intervention: Dapagliflozin 5 mg/day
Number of subjects: 597

Group type: EXPERIMENTAL
Intervention: Dapagliflozin 10 mg/day
Number of subjects: 597

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 597

Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Number of subjects: 597
Study: 18279865

Group type: EXPERIMENTAL
Intervention: 5.5-mm diameter 4-way angulation endoscope (XGIF-XP240N2, Olympus)
Number of subjects: 291

Group type: COMPARATOR
Intervention: 5.2-mm diameter 2-way angulation endoscope (GIF-N260, Olympus)
Number of subjects: 291
Study: 16818537

Group type: EXPERIMENTAL
Intervention: Suprapubic aspiration
Number of subjects: 58

Group type: COMPARATOR
Intervention: Transurethral catheterization
Number of subjects: 58
Study: 12767952

Group type: EXPERIMENTAL
Intervention: Test-and-treat (T & T) strategy for Helicobacter pylori (HP), n = 321
Number of subjects: 650

Group type: COMPARATOR
Intervention: Usual care, n = 329
Number of subjects: 650
Study: 11147379

Group type: EXPERIMENTAL
Intervention: Cisatracurium (0.2 mg/kg) administered IV
Number of subjects: 38

Group type: COMPARATOR
Intervention: Control (C) group
Number of subjects: 38
Study: 9499585

Group type: EXPERIMENTAL
Intervention: At-risk participants
Number of subjects: 50

Group type: COMPARATOR
Intervention: Controls
Number of subjects: 50
Study: 8224303

Group type: EXPERIMENTAL
Intervention: Nasal trabeculectomy
Number of subjects: 60

Group type: COMPARATOR
Intervention: Superior trabeculectomy
Number of subjects: 60

Group type: COMPARATOR
Intervention: Temporal trabeculectomy
Number of subjects: 60
Study: 3531953

Group type: EXPERIMENTAL
Intervention: 100 IU of salmon calcitonin subcutaneously daily for 28 days
Number of subjects: 40

Group type: COMPARATOR
Intervention: Physiological solution (placebo) administered daily for 28 days
Number of subjects: 40
Study: 30409830

Group type: EXPERIMENTAL
Intervention: Oral cyclophosphamide (CYC) for 1 year in SLS I
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Oral cyclophosphamide (CYC) for 1 year followed by 1 year of placebo in SLS II
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: 2 years of mycophenolate mofetil in SLS II
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Decline in forced vital capacity (FVC) and diffusing capacity for carbon monoxide (DLCO) over 2 years
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Baseline skin score and older age
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Short-term changes in surrogate measures of SSc-ILD progression
Number of subjects: 300
Study: 29750475

Group type: EXPERIMENTAL
Intervention: Losartan
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Allopurinol
Number of subjects: 86

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 86
Study: 26890095

Group type: EXPERIMENTAL
Intervention: Active tRNS
Number of subjects: 16

Group type: COMPARATOR
Intervention: Sham tRNS
Number of subjects: 16
Study: 24951020

Group type: EXPERIMENTAL
Intervention: Fibrinogen concentrate (60 mg/kg)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Cryoprecipitate (10 mL/kg)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 63
Study: 22252356

Group type: EXPERIMENTAL
Intervention: ID diet (1,200 mg/hen per day)
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: SPL diet (1,010 mg/hen per day)
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: SP diet (600 mg/hen per day)
Number of subjects: 240

Group type: COMPARATOR
Intervention: ID diet (1,010 mg/hen per day)
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: IDL diet (1,200 mg/hen per day)
Number of subjects: 240
Study: 20139218

Group type: EXPERIMENTAL
Intervention: Empirical antibiotics
Number of subjects: 309

Group type: EXPERIMENTAL
Intervention: Empirical delayed antibiotics (by 48 hours)
Number of subjects: 309

Group type: EXPERIMENTAL
Intervention: Targeted antibiotics based on high symptom score
Number of subjects: 309

Group type: EXPERIMENTAL
Intervention: Targeted antibiotics based on dipstick results
Number of subjects: 309

Group type: EXPERIMENTAL
Intervention: Targeted antibiotics based on midstream urine analysis
Number of subjects: 309

Group type: COMPARATOR
Intervention: Immediate antibiotics
Number of subjects: 309
Study: 17703389

Group type: EXPERIMENTAL
Intervention: Transpancreatic septotomy
Number of subjects: 306

Group type: COMPARATOR
Intervention: Needle‐knife sphincterotomy
Number of subjects: 306

Group type: COMPARATOR
Intervention: Conventional pull‐type sphincterotomy
Number of subjects: 306